Dx Shops Have to ‘Pound the Pavement’ Like Big Pharma, Genomic Health Official Says | GenomeWeb
SAN FRANCISCO – Multiple studies, peer-reviewed publications, and pounding the pavement with an aggressive sales force like big pharma is the strategy behind Genomic Health’s success in getting physicians to adopt and insurance companies to cover its breast cancer recurrence test OncotypeDX.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.